Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

References

• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153:13-9; PMID:23172303; http://dx.doi.org/10.1093/jb/mvs136
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21:154-65; PMID:19230644; http://dx.doi.org/10.1016/j.ceb.2008.12.012
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146:873-87; PMID:21925313; http://dx.doi.org/10.1016/j.cell.2011.08.039
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9:777-94; PMID:16364190; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00379.x
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8:299-309; PMID:16226705; http://dx.doi.org/10.1016/j.ccr.2005.09.005
   PubMed Web of Science ®Google Scholar
• Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002; 2:135-56; PMID:12188915; http://dx.doi.org/10.2174/1568009023333881
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-8; PMID:7525076; http://dx.doi.org/10.1016/0092-8674(94)90187-2
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195-27
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-4; ;PMID:7683111; http://dx.doi.org/10.1038/362841a0
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324-30; PMID:8640821
   PubMed Web of Science ®Google Scholar
• Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95:8795-800; PMID:9671758; http://dx.doi.org/10.1073/pnas.95.15.8795
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-40; PMID:19720927; http://dx.doi.org/10.1200/JCO.2008.19.8721
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76; PMID:18160686; http://dx.doi.org/10.1056/NEJMoa072113
   PubMed Web of Science ®Google Scholar
• Lee SH. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34:1223-6; PMID:21910042; http://dx.doi.org/10.1007/s12272-011-0821-9
   PubMed Web of Science ®Google Scholar
• Lee WS, Pyun BJ, Kim SW, Shim SR, Nam JR, Yoo JY, Jin Y, Jin J, Kwon YG, Yun CO, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs 2015;5:957-968
   Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-9; PMID:17947719; http://dx.doi.org/10.1200/JCO.2007.12.2440
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6; PMID:4938153; http://dx.doi.org/10.1056/NEJM197108122850711
   PubMed Web of Science ®Google Scholar
• Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972; 22:226-9; PMID:4625047; http://dx.doi.org/10.3322/canjclin.22.4.226
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975; 82:96-100; PMID:799908; http://dx.doi.org/10.7326/0003-4819-82-1-96
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333:328-35; PMID:15961063; http://dx.doi.org/10.1016/j.bbrc.2005.05.132
   PubMed Web of Science ®Google Scholar
• Shah MA. Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. Nat Rev Clin Oncol 2014; 11:10-1; PMID:24300880; http://dx.doi.org/10.1038/nrclinonc.2013.231
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31-9; PMID:24094768; http://dx.doi.org/10.1016/S0140-6736(13)61719-5
   PubMed Web of Science ®Google Scholar
• Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58:1952-9; PMID:9581838
   PubMed Web of Science ®Google Scholar
• Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett 1999; 136:203-13; PMID:10355750; http://dx.doi.org/10.1016/S0304-3835(98)00324-3
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17:155-61; PMID:9770111; http://dx.doi.org/10.1023/A:1006094117427
   PubMed Web of Science ®Google Scholar
• Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene 2003; 22:9097-106; PMID:14663488; http://dx.doi.org/10.1038/sj.onc.1207104
   PubMed Web of Science ®Google Scholar
• Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007; 13:1663-74; PMID:17363519; http://dx.doi.org/10.1158/1078-0432.CCR-06-2854
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology 2000; 2:45-59; PMID:11302254
   PubMed Web of Science ®Google Scholar
• Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C, Niu Q, Guo D, et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PloS one 2013; 8:e57188; PMID:23536763; http://dx.doi.org/10.1371/journal.pone.0057188
   PubMed Web of Science ®Google Scholar
• Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70:2213-23; PMID:20197469; http://dx.doi.org/10.1158/0008-5472.CAN-09-1977
   PubMed Web of Science ®Google Scholar
• Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 2008; 267:26-36; PMID:18420342; http://dx.doi.org/10.1016/j.canlet.2008.03.008
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr., Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006; 4:1-10; quiz 1 2; PMID:17139244
   PubMedGoogle Scholar
• Miyake K, Tsuchida K, Sugino H, Imura S, Morine Y, Fujii M, Shimada M. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-α. Cancer Chemother Pharmacol 2007; 59:113-26; PMID:16699793; http://dx.doi.org/10.1007/s00280-006-0250-5
   PubMed Web of Science ®Google Scholar
• Cartwright TH. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin Colorectal Cancer 2013; 12:86-94; PMID:23562587; http://dx.doi.org/10.1016/j.clcc.2012.12.001
   PubMed Web of Science ®Google Scholar
• Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 2003; 9:1399-405; PMID:12684411
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G, Boiardi A. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62:297-303; PMID:12777082; http://dx.doi.org/10.1023/A:1023367223575
   PubMed Web of Science ®Google Scholar
• Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004; 64:6503-10; PMID:15374961; http://dx.doi.org/10.1158/0008-5472.CAN-04-0452
   PubMed Web of Science ®Google Scholar
• Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65:1678-86; PMID:15753362; http://dx.doi.org/10.1158/0008-5472.CAN-04-2921
   PubMed Web of Science ®Google Scholar
• Ng K, Kim R, Kesari S, Carter B, Chen CC. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncology 2012; 107:1-12; PMID:22002595; http://dx.doi.org/10.1007/s11060-011-0714-2
   PubMed Web of Science ®Google Scholar
• Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw 2011; 9:403-7; PMID:21464145
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013; 19:1584-96; PMID:24309662; http://dx.doi.org/10.1038/nm.3407
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-802; PMID:17212999; http://dx.doi.org/10.1016/j.clinthera.2006.11.015
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170
   PubMed Web of Science ®Google Scholar
• Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9:145-56; PMID:20053776; http://dx.doi.org/10.1158/1535-7163.MCT-09-0554
   PubMed Web of Science ®Google Scholar
• Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000; 92:326-33; PMID:10659021; http://dx.doi.org/10.3171/jns.2000.92.2.0326
   PubMed Web of Science ®Google Scholar
• Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, Hong SC, Shin HJ, Kim JH, Eoh W, et al. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 2004; 11:263-8; PMID:14719052
   PubMed Web of Science ®Google Scholar